Generation Bio Co. Stock Price, News & Analysis

Generation Bio (Nasdaq:GBIO) has announced that CEO Geoff McDonough, M.D., will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18th at 3:00 p.m. EST. Investors can access a live webcast on the company's investor website, with a replay available for 30 days after the event.

Generation Bio specializes in genetic medicines aimed at providing sustainable, redosable treatments for both rare and common diseases. Their innovative platform utilizes a unique non-viral genetic medicine, featuring closed-ended DNA (ceDNA) and a specialized delivery system known as cell-targeted lipid nanoparticles (ctLNP). This technology is designed to enable long-lasting treatment effects from a single dose and has the potential to significantly scale up production.

Generation Bio Co. (Nasdaq:GBIO) has appointed Yalonda Howze, J.D., as its chief legal officer and secretary. Howze brings nearly two decades of legal experience in biotechnology and life sciences, having previously served at Codiak BioSciences and as a partner at Mintz Levin. CEO Geoff McDonough expressed optimism about her contributions to the company’s ambitious goal of developing transformative genetic medicines for rare and prevalent diseases. Generation Bio focuses on innovative genetic therapies using its proprietary non-viral delivery system, aiming for long-lasting and adjustable treatments.

Moderna and Generation Bio have formed a strategic collaboration to develop novel nucleic acid therapeutics. Moderna has secured an option to license Generation Bio's lipid nanoparticle technology for two immune cell and two liver programs, with the possibility of a third. As part of the deal, Generation Bio will receive a $40 million upfront cash payment, along with a $36 million equity investment from Moderna, which will also fund all research and development activities. The collaboration aims to enhance the delivery of genetic medicines, targeting both immune cells and liver tissues.

On March 21, 2023, Generation Bio (Nasdaq:GBIO) announced its participation in the BMO Biopharma Spotlight Series: Novel Technologies for the Delivery of Genetic Medicines. The virtual event will occur on March 28 at 10:00 a.m. ET.

Generation Bio is focused on developing genetic medicines for rare and prevalent diseases. Their innovative platform features closed-ended DNA (ceDNA), a cell-targeted lipid nanoparticle delivery system (ctLNP), and a proprietary cell-free rapid enzymatic synthesis (RES) process. This technology aims to provide durable, redosable treatments potentially capable of producing hundreds of millions of doses, thus broadening access to genetic therapies globally.

Generation Bio (Nasdaq:GBIO), a biotechnology firm focused on genetic medicines, announced that Geoff McDonough, M.D., the president and CEO, will speak at the Gene Therapy panel during the 43rd Annual Cowen Healthcare Conference. This event is scheduled for March 6th at 10:30 a.m. EST in Boston, MA. A live webcast will be accessible on the company's investor website, with a replay available for 30 days post-event.

Generation Bio aims to provide innovative treatments for rare and prevalent diseases using its proprietary non-viral genetic medicine platform. This includes closed-ended DNA (ceDNA) technology and cell-targeted lipid nanoparticle delivery systems.

Generation Bio Co. (Nasdaq: GBIO) announced strategic priorities for 2023 and reported its 2022 financial results. The company aims to lead in non-viral DNA therapeutics, focusing on optimized delivery systems to enhance drug efficacy. A strong cash balance of $279.1 million is expected to fund operations into 2025. For 2022, the company reported a net loss of $136.6 million or $2.35 per share, with R&D expenses of $96.7 million. Upcoming plans include demonstrating Factor VIII expression in non-human primates and developing novel lipid nanoparticle systems for targeted therapies.

Generation Bio (Nasdaq: GBIO) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference scheduled for January 10, 2023, at 4:30 p.m. PST in San Francisco, CA. The company focuses on innovative genetic medicines targeting rare and prevalent diseases. A live webcast of the presentation will be available on the investor section of their website. Generation Bio's platform features unique technologies designed to enable durable, redosable treatments with large genetic payloads for specific cell types.

Generation Bio Co. (Nasdaq: GBIO) reported a cash position of $301.2 million as of September 30, 2022, expected to fund operations into 2025. The company focuses on developing genetic medicines, particularly for hemophilia A, utilizing its proprietary delivery system. Third quarter R&D expenses totaled $21.2 million, down from $22.0 million the previous year, while G&A expenses rose to $11.5 million, up from $9.7 million. The net loss narrowed to $31.3 million or $0.53 per share, compared to $31.9 million or $0.56 per share a year ago.

Generation Bio Co. (Nasdaq: GBIO) will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on September 29th at 10:30 a.m. ET in New York. A live webcast will be available on the company's investor website, and a replay will be accessible for 30 days post-event.

Generation Bio focuses on developing genetic medicines for rare and prevalent diseases using its unique platform, which includes closed-ended DNA (ceDNA) technology and a scalable manufacturing process. The aim is to provide durable, redosable treatments for patients worldwide.